Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.
Syncope and sudden death are features of schizophrenia that can be attributed to ischaemic heart disease, the use of antipsychotics (because of proarrhythmia or other reasons such as pharyngeal dyskinesia) or the psychiatric disease itself. Cases have been described with most antipsychotics and have led to the withdrawal, temporary suspension from the market or restricted use of antipsychotics, such as sultopride, droperidol, sertindole or thioridazine. Reviewing the available data shows that all antipsychotics tested affect the cardiac potassium channel, with the concentration that produces 50% inhibition (IC50) ranging from 1 nmol/L (haloperidol) to 6 micromol/L (olanzapine). Experimental in vitro or in vivo electrophysiological studies have shown a dose-dependent increase in the duration of the action potential with various degrees of indicators of serious arrhythmogenicity. However, this does not always translate clinically into an increased duration of the QT interval or increased risk of torsade de pointes or sudden death in clinical trials or pharmacoepidemiological studies. In turn, QT prolongation in clinical trials does not always translate to an increased risk of torsade de pointes or sudden death. The reasons for these apparent discrepancies are unclear and could be related to insufficiently powered field studies, low plasma and tissue drug concentrations with reference to in vitro data or drug effects on other receptors or ion channels that have a protective effect. Alternatively, risks that were not apparent from preclinical or clinical data could be related to the use of the drug in high-risk patients, metabolic interactions or other factors that would only be encountered in large postmarketing populations. The assessment of cardiovascular safety, both preclinical and during premarketing clinical trials, needs to be supported by appropriately powered pharmacoepidemiology studies.
Titier
Karine
K
Dept de Pharmacologie, Université Victor Ségalen, CHU de Bordeaux, INSERM Réseau de Pharmacoépidémiologie, Bordeaux, France. karine.titier@pharmaco.u-bordeaux2.fr
Girodet
Pierre-Olivier
PO
Verdoux
Hélène
H
Molimard
Mathieu
M
Bégaud
Bernard
B
Haverkamp
Wilhelm
W
Lader
Malcolm
M
Moore
Nicholas
N
D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D027682:Cation Transport Proteins / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D016757:Death, Sudden, Cardiac; D004562:Electrocardiography / Q000187:drug effects; D004594:Electrophysiology; D051638:Ether-A-Go-Go Potassium Channels; D006801:Humans; D018408:Patch-Clamp Techniques; D015221:Potassium Channels / Q000187:drug effects / Q000502:physiology; D024642:Potassium Channels, Voltage-Gated / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy; D016171:Torsades de Pointes / Q000139:chemically induced*
D014150:Antipsychotic Agents; D027682:Cation Transport Proteins; D051638:Ether-A-Go-Go Potassium Channels; C092509:KCNH6 protein, human; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated